Research Paper Volume 13, Issue 14 pp 18701—18717

Development and validation of a novel epigenetic-related prognostic signature and candidate drugs for patients with lung adenocarcinoma


Figure 5. Construction of the epigenetic-based prognostic risk signature in the TCGA cohort. (A) The risk score distribution of LUAD patients. (B) Survival status and duration of patients. (C) Survival curves for the low risk and high risk groups. (D) Time-independent receiver operating characteristic (ROC) analysis of risk scores for prediction the overall survival in the TCGA set.